Table 1 of Verdina, Mol Vis 2021; 27:78-94.


Table 1. Demographic, clinical and genetic data of the study population.

ID Age Sex Eye Onset BCVA logMar Snellen sph eq. Affected sector GENE/cDNA(protein)
P1 (AG)* 69 F R 40 0 20/20 0 INF, NAS RHO /c.568G>A(p.Asp190Asn)
L 0 20/20 0 INF, NAS
P2 (AM)* 65 M R 36 0 20/20 -2 INF RHO /c.568G>A(p.Asp190Asn)
L 0 20/20 -2 INF
P3 (BA) 53 F R 46 0.1 20/25 -2.5 INF
L 0.3 20/40 -3.5 INF
P4 (FO) 77 F R 69 0.52 20/60 3.5 INF, NAS
L 0.1 20/25 0.75 INF, NAS
P5 (FA) 57 M R 44 0 20/20 0 INF RHO/c.568G>A(p.Asp190Asn) 
L 0 20/20 0 INF
P6 (GL) 64 M R 62 0 20/20 0 INF, TEMP RHO /c.568G>A(p.Asp190Asn)
L 0 20/20 -1.25 INF, TEMP
P7 (PP) 58 F R 50 0 20/20 2 INF,TEMP,NAS
L 0 20/20 2.25 INF,TEMP,NAS
P8 (RM) 40 F R 40 0 20/20 0 INF RHO /c.548T>C (p.Leu183Pro)
L 0 20/20 0 INF
P9 (SA)** 63 M R 52 0 20/20 0.5 INF RHO /c.568G>A (p.Asp190Asn)
L 0 20/20 0.5 INF
P10 (SE)** 19 F R 11 0 20/20 0.75 INF, TEMP
L 0 20/20 0.25 INF, TEMP
P11 (SF)** 23 F R 21 0 20/20 -0.75 INF, NAS RHO /c.568G>A (p.Asp190Asn)
L 0 20/20 -0.5 INF, NAS
P12 (SL)** 22 F R 21 0 20/20 0 NAS RHO /c.568G>A (p.Asp190Asn)
L 0 20/20 0 TEMP
P13(SM)** 57 M R 48 0 20/20 0 INF RHO /c.568G>A (p.Asp190Asn)
L 0 20/20 0 INF
P14 (SS)** 29 F R 28 0 20/20 -2 INF RHO /c.568G>A (p.Asp190Asn)
L 0 20/20 -2 INF GUCY2D /c.2179G>A (p.Gly727Ser)
P15 (TA) 56 M R 50 0.4 20/50 -8 INF USH2A/c.2173G>C(p.Gly713Arg); ROM1 /c.178C>A (p.Pro60Thr)c.323C>T (p.Thr108Met)